MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Triumeqhcp.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Triumeqhcp.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Triumeqhcp.com most likely does not offer any adult content.
Popular pages
-
Home | See Boxed Warning for TRIUMEQ & TRIUMEQ PD (abacavir, dolutegravir, lamivudine)
Learn more about TRIUMEQ, a combination of abacavir, dolutegravir, and lamivudine for the treatment of human immunodeficiency virus type 1 (HIV‐1) infection.
-
Dosing Considerations | See Boxed Warning for TRIUMEQ & TRIUMEQ PD (abacavir, dolutegravir
Read important information about dosing and administration of TRIUMEQ (abacavir, dolutegravir, lamivudine), a treatment for HLA‐B*5701‐negative patients with HIV‐1.
-
Stay Connected | TRIUMEQ & TRIUMEQ PD Official HCP Website
Sign up for ongoing communication about HIV-1 resources and tools.
-
Clinical Trials | See Boxed Warning for TRIUMEQ (abacavir, dolutegravir, lamivudine)
Learn about virologic efficacy, resistance, and safety data from two Phase 3 trials for TRIUMEQ for the treatment of HLA‐B*5701‐negative adult patients with HIV‐1.
-
HLA Screening | See Boxed Warning for TRIUMEQ & TRIUMEQ PD (abacavir, dolutegravir, lamivudine)
Learn about HLA screening and Phase 3 HLA trials with TRIUMEQ (abacavir, dolutegravir, lamivudine), a treatment for HLA‐B*5701‐negative patients with HIV‐1.
-
Risks and Side Effects | See Boxed Warning for TRIUMEQ & TRIUMEQ PD (abacavir, dolutegravir
Learn about the possible risks and side effects of TRIUMEQ (abacavir, dolutegravir, lamivudine), a treatment for HLA‐B*5701‐negative patients with HIV‐1.